Australia markets closed

Sorrento Therapeutics, Inc. (SRNE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.9600-0.0700 (-3.45%)
At close: 04:00PM EDT
1.9400 -0.02 (-1.02%)
After hours: 07:52PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 809.01M
Enterprise value 787.24M
Trailing P/E N/A
Forward P/E 1.10
PEG ratio (5-yr expected) N/A
Price/sales (ttm)11.27
Price/book (mrq)3.57
Enterprise value/revenue 13.80
Enterprise value/EBITDA -1.64

Trading information

Stock price history

Beta (5Y monthly) 2.43
52-week change 3-79.77%
S&P500 52-week change 3-11.08%
52-week high 311.0700
52-week low 31.1500
50-day moving average 31.6474
200-day moving average 34.0234

Share statistics

Avg vol (3-month) 310.17M
Avg vol (10-day) 317.4M
Shares outstanding 5388.95M
Implied shares outstanding 6N/A
Float 8358.91M
% held by insiders 15.79%
% held by institutions 133.60%
Shares short (30 May 2022) 454.08M
Short ratio (30 May 2022) 46
Short % of float (30 May 2022) 414.07%
Short % of shares outstanding (30 May 2022) 413.90%
Shares short (prior month 28 Apr 2022) 454.66M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:25
Last split date 331 July 2013

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin 0.00%
Operating margin (ttm)-679.18%

Management effectiveness

Return on assets (ttm)-32.96%
Return on equity (ttm)-206.57%

Income statement

Revenue (ttm)57.03M
Revenue per share (ttm)0.19
Quarterly revenue growth (yoy)29.00%
Gross profit (ttm)-167.05M
EBITDA -374.52M
Net income avi to common (ttm)-471.65M
Diluted EPS (ttm)-1.5270
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)270.66M
Total cash per share (mrq)0.71
Total debt (mrq)248.88M
Total debt/equity (mrq)110.03
Current ratio (mrq)1.62
Book value per share (mrq)0.62

Cash flow statement

Operating cash flow (ttm)-317.12M
Levered free cash flow (ttm)-160.27M